Ga-68-PSMA PET/CT for Prostate Cancer

被引：4
作者：
Hellwig, D. [1 ,2 ]
Moosbauer, J. [2 ]
Eilles, C. [2 ]
机构：
[1] Univ Klikikum Saarlandes, Klin Nukl Med, Homburg, Germany
[2] Univ Klinikum Regensburg, Abt Nukl Med, D-93053 Regensburg, Germany
来源：
AKTUELLE UROLOGIE | 2014年 / 45卷 / 06期
关键词：
PSMA; prostate cancer; PET/CT; Ga-68-Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; MEMBRANE ANTIGEN-EXPRESSION; ANDROGEN-DEPRIVATION THERAPY; MONOCLONAL-ANTIBODIES; RADICAL PROSTATECTOMY; EXTRACELLULAR DOMAIN; PSMA LIGAND; TUMOR; RECURRENCE; TARGET; BIODISTRIBUTION;
D O I：
10.1055/s-0034-1395529
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Prostate-specific membrane antigen (PSMA) is expressed as a cell surface protein physiologically in the prostate and can be found in all stages of prostate cancer. Even in castration-resistant prostate cancers, this overexpression of PSMA occurs. Due to the enzymatic activity of PSMA it was possible develop specific inhibitors from which "small molecule" radiopharmaceuticals were derived. By coupling the specific binding motif glutamate-urea-lysine with the chelator HBED-CC, which complexes Ga-68 very effectively, a new radiopharmaceutical is available for Ga-68-PSMA-PET/CT. According to the first results in patients with prostate carcinoma, this new diagnostic tool exhibited advantages in image quality compared to choline-PET/CT. An initial study demonstrated the higher contrast of the PET signal and an improved diagnostic accuracy. The properties of even further new PSMA PET radiopharmaceuticals can be of increasing importance for the diagnostic work-up of prostate cancer in all stages. In conjunction with therapeutic PSMA radiopharmaceuticals, a new field of theragnostics is opened.
引用
收藏
页码：457 / 463
页数：7
相关论文
共 46 条
[1]   PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].
Afshar-Oromieh, A. ;
Malcher, A. ;
Eder, M. ;
Eisenhut, M. ;
Linhart, H. G. ;
Hadaschik, B. A. ;
Holland-Letz, T. ;
Giesel, F. L. ;
Kratochwil, C. ;
Haufe, S. ;
Haberkorn, U. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495
[2]   [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH [J].
Afshar-Oromieh, A. ;
Haberkorn, U. ;
Eder, M. ;
Eisenhut, M. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) :1085-1086
[3]   Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].
Afshar-Oromieh, Ali ;
Zechmann, Christian M. ;
Malcher, Anna ;
Eder, Matthias ;
Eisenhut, Michael ;
Linhart, Heinz G. ;
Holland-Letz, Tim ;
Hadaschik, Boris A. ;
Giesel, Frederik L. ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20
[4]  
[Anonymous], 2011, WORLD MOL IM C
[5]  
[Anonymous], INTERDISZIPLINARE LE
[6]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[7]   18F-fluorocholine for prostate cancer imaging: a systematic review of the literature [J].
Bauman, G. ;
Belhocine, T. ;
Kovacs, M. ;
Ward, A. ;
Beheshti, M. ;
Rachinsky, I. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) :45-55
[8]  
Beheshti M, 2012, J NUCL MED, V53
[9]   Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics [J].
Beheshti, Mohsen ;
Haim, Silke ;
Zakavi, Rasoul ;
Steinmair, Martin ;
Waldenberger, Peter ;
Kunit, Thomas ;
Nader, Michael ;
Langsteger, Werner ;
Loidl, Wolfgang .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (06) :833-840
[10]  
Chang SS, 1999, CLIN CANCER RES, V5, P2674
12345